Evidence map›Paper›PMID 32504575›Full record

Trial reportThe lancet. HIV2020

Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial.

Kathleen E Wirth, Tendani Gaolathe, Molly Pretorius Holme, Mompati Mmalane, Etienne Kadima, Unoda Chakalisa, Kutlo Manyake, Atang Matildah Mbikiwa, Selebaleng V Simon, Rona Letlhogile and 31 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The lancet. HIV, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01965470 (Botswana Combination Prevention Project), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01965470 phase4completednot on this map

Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2013 to 2018ConditionsHIVArmsCombination Prevention, Enhanced Care
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 7 institutions in 2 countries.

Kathleen E WirthDepartment of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA, USA. Electronic address: kathleen.wirth@gmail.com.
Tendani GaolatheBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Molly Pretorius HolmeDepartment of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA.
Mompati MmalaneBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Etienne KadimaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Unoda ChakalisaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Kutlo ManyakeBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Atang Matildah MbikiwaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Selebaleng V SimonBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Rona LetlhogileBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Kutlwano MukokomaniBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Erik van WidenfeltBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Sikhulile MoyoDepartment of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Kara BennettBennett Statistical Consulting, Ballston Lake, NY, USA.
Jean LeidnerGoodtables Data Consulting, Norman, Oklahoma, USA.
Kathleen M PowisDepartment of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA.
Refeletswe LebelonyaneMinistry of Health and Wellness, Botswana, Gaborone, Botswana.
Mary Grace AlwanoCenters for Disease Control and Prevention-Botswana, Gaborone, Botswana.
Joseph JarvisBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Centers for Disease Control and Prevention-Botswana, Gaborone, Botswana.
Scott L Dryden-PetersonDepartment of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Coulson KgathiBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Janet MooreCenters for Disease Control and Prevention, Atlanta, GA, USA.
Pam BachanasCenters for Disease Control and Prevention, Atlanta, GA, USA.
Elliot RaizesCenters for Disease Control and Prevention, Atlanta, GA, USA.
William AbramsCenters for Disease Control and Prevention-Botswana, Gaborone, Botswana.
Lisa BlockCenters for Disease Control and Prevention, Atlanta, GA, USA; Intellectual Concepts, Atlanta, GA, USA.
Baraedi SentoTebelopele Voluntary Counseling and Testing Center, Gaborone, Botswana.
Vlad NovitskyDepartment of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA.
Shenaaz El-HalabiMinistry of Health and Wellness, Botswana, Gaborone, Botswana.
Tafireyi MarukutiraCenters for Disease Control and Prevention-Botswana, Gaborone, Botswana.
Lisa A MillsCenters for Disease Control and Prevention-Botswana, Gaborone, Botswana.
Connie SextonCenters for Disease Control and Prevention, Atlanta, GA, USA.
Sherri PalsCenters for Disease Control and Prevention, Atlanta, GA, USA.
Roger L ShapiroDepartment of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA.
Rui WangDepartment of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA, USA; Harvard Pilgrim Health Care Institute, Boston, MA, USA.
Quanhong LeiDepartment of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA, USA.
Victor DeGruttolaDepartment of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA, USA.
Joseph MakhemaDepartment of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Myron EssexDepartment of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Shahin LockmanDepartment of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Eric J Tchetgen TchetgenDepartment of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA, USA; Department of Statistics, The Wharton School at the University of Pennsylvania, Philadelphia, PA, USA.
Botswana Harvard AIDS Institute Partnership · BWHarvard University · USCenters for Disease Control and Prevention · USUniversity of Botswana · BWMinistry of Health · BWHarvard Pilgrim Health Care · USIntellectual Ventures (United States) · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
INTERNATIONAL TRAINING IN AIDS-RELATED EPIDEMIOLOGYD43TW000004 · FIC · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 1988 to 2012
$13.4M
Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Methods to Advance the HIV Prevention Research AgendaR37AI051164 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI DEGRUTTOLA, VICTOR GERARD · 2012 to 2019
$3.3M
Next Generation Missing Data Methods in HIV ResearchR01AI127271 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI TCHETGEN TCHETGEN, ERIC JOEL · 2017 to 2021
$3.2M
Covid-19-related cervical cancer treatment interruption and role of neoadjuvant chemotherapyR01CA236546 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI DRYDEN-PETERSON, SCOTT · 2019 to 2023
$2.5M
Novel Designs and Methods to Remove Hidden Confounding Bias in Health SciencesR01AG065276 · NIA · UNIVERSITY OF PENNSYLVANIA · PI TCHETGEN TCHETGEN, ERIC JOEL · 2020 to 2024
$2.4M
Theory and methods for mediation and interactionR01CA222147 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI TCHETGEN TCHETGEN, ERIC JOEL, VANDERWEELE, TYLER · 2018 to 2022
$2.1M
Identification and Inference for Longitudinal Causal Mediation Analysis in HIVR01AI104459 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI SHPITSER, ILYA, VANDERWEELE, TYLER · 2013 to 2017
$2.0M
Mentoring in Patient-Oriented HIV Research in the Era of Universal ARTK24AI131928 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAHIN LOCKMAN · 2017 to 2026
$1.9M
Network modeling and robust estimation of the intraclass correlation coefficient to inform the design and analysis of cluster randomized trials for infectious diseasesR01AI136947 · NIAID · HARVARD PILGRIM HEALTH CARE, INC. · PI WANG, RUI · 2018 to 2020
$759k
CGH CDC HHS U2G GH001911FIC NIH HHS D43 TW000004FIC NIH HHS D43 TW009610FIC NIH HHS D43 TW010543NCI NIH HHS R01 CA222147NCI NIH HHS R01 CA236546NIAID NIH HHS K23 AI091434NIAID NIH HHS K24 AI131928NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI104459NIAID NIH HHS R01 AI127271NIAID NIH HHS R01 AI136947NIAID NIH HHS R37 AI051164NIA NIH HHS R01 AG065276NICHD NIH HHS K23 HD070774Wellcome TrustWellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

backgroundIn settings with high HIV prevalence and treatment coverage, such as Botswana, it is unknown whether uptake of HIV prevention and treatment interventions can be increased further. We sought to determine whether a community-based intervention to identify and rapidly treat people living with HIV, and support male circumcision could increase population levels of HIV diagnosis, treatment, viral suppression, and male circumcision in Botswana.

methodsThe Ya Tsie Botswana Combination Prevention Project study was a pair-matched cluster-randomised trial done in 30 communities across Botswana done from Oct 30, 2013, to June 30, 2018. 15 communities were randomly assigned to receive HIV prevention and treatment interventions, including enhanced HIV testing, earlier antiretroviral therapy (ART), and strengthened male circumcision services, and 15 received standard of care. The first primary endpoint of HIV incidence has already been reported. In this Article, we report findings for the second primary endpoint of population uptake of HIV prevention services, as measured by proportion of people known to be HIV-positive or tested HIV-negative in the preceding 12 months; proportion of people living with HIV diagnosed and on ART; proportion of people living with HIV on ART with viral suppression; and proportion of HIV-negative men circumcised. A longitudinal cohort of residents aged 16-64 years from a random, approximately 20% sample of households across the 15 communities was enrolled to assess baseline uptake of study outcomes; we also administered an end-of-study survey to all residents not previously enrolled in the longitudinal cohort to provide study end coverage estimates. Differences in intervention uptake over time by randomisation group were tested via paired Student's t test. The study has been completed and is registered with ClinicalTrials.gov (NCT01965470).

findingsIn the six communities participating in the end-of-study survey, 2625 residents (n=1304 from standard-of-care communities, n=1321 from intervention communities) were enrolled into the 20% longitudinal cohort at baseline from Oct 30, 2013, to Nov 24, 2015. In the same communities, 10 791 (86%) of 12 489 eligible enumerated residents not previously enrolled in the longitudinal cohort participated in the end-of-study survey from March 30, 2017, to Feb 25, 2018 (5896 in intervention and 4895 in standard-of-care communities). At study end, in intervention communities, 1228 people living with HIV (91% of 1353) were on ART; 1166 people living with HIV (88% of 1321 with available viral load) were virally suppressed, and 673 HIV-negative men (40% of 1673) were circumcised in intervention communities. After accounting for baseline differences, at study end the proportion of people living with HIV who were diagnosed was significantly higher in intervention communities (absolute increase of 9% to 93%) compared with standard-of-care communities (absolute increase of 2% to 88%; prevalence ratio [PR] 1·08 [95% CI 1·02-1·14], p=0·032). Population levels of ART, viral suppression, and male circumcision increased from baseline in both groups, with greater increases in intervention communities (ART PR 1·12 [95% CI 1·07-1·17], p=0·018; viral suppression 1·13 [1·09-1·17], p=0·017; male circumcision 1·26 [1·17-1·35], p=0·029).

interpretationIt is possible to achieve very high population levels of HIV testing and treatment in a high-prevalence setting. Maintaining these coverage levels over the next decade could substantially reduce HIV transmission and potentially eliminate the epidemic in these areas.

fundingUS President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention.

Indexed as

AdolescentAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBotswanaCircumcision, MaleFemaleHIV-1HIV InfectionsHumansLongitudinal StudiesMaleMass ScreeningMiddle AgedPrevalenceSurveys and QuestionnairesAnti-HIV Agents

Identifiers

PMID32504575
PMCPMC7864245
OpenAlexW3033529411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.